Ulcerative colitis (UC) is a persistent, periodically reoccurring inflammatory condition that impacts the gastrointestinal tract. Angelicone, a principal compound extracted from Angelica sinensis, may offer a potential alternative therapeutic approach for UC through the downregulation of inflammatory mediators. Nonetheless, the pharmacological impacts and molecular pathways of angelicone in UC management, particularly in relation to gut microbiota, remain unexplored. The current study scrutinized the modifications in gut microbiota in mice afflicted with UC, induced by 3% dextran sodium sulfate (DSS), utilizing 16S rRNA sequencing. The study demonstrated that angelicone substantially enhanced clinical indices, mitigated colonic damage, decreased cytokine levels, and reestablished the integrity of the intestinal epithelial barrier in UC mice. Furthermore, we discerned distinct bacterial genera that were responsive to angelicone treatment. Importantly, angelicone augmented the abundance of gut microbiota and partially reinstated the disrupted intestinal microbial composition, inclusive of the phyla Proteobacteria, Firmicutes, and Bacteroidetes. To summarize, our research offers novel perspectives into the intervention mechanisms of angelicone in the treatment of UC.

中文翻译：

---

当归酮通过调节肠道菌群改善小鼠溃疡性结肠炎

溃疡性结肠炎 （UC） 是一种影响胃肠道的持续性、周期性复发的炎症性疾病。Angelicone 是从当归中提取的主要化合物，可能通过下调炎症介质为 UC 提供一种潜在的替代治疗方法。尽管如此，当归菌在 UC 管理中的药理学影响和分子途径，特别是与肠道微生物群相关的影响和分子途径，仍未得到探索。目前的研究利用 16S rRNA 测序仔细检查了由 3% 葡聚糖硫酸钠 （DSS） 诱导的 UC 小鼠肠道微生物群的修饰。研究表明，当归酮显着提高了 UC 小鼠的临床指标，减轻了结肠损伤，降低了细胞因子水平，并重建了肠上皮屏障的完整性。此外，我们识别出对当归松治疗有反应的不同细菌属。重要的是，当归酮增加了肠道微生物群的丰度，并部分恢复了被破坏的肠道微生物组成，包括变形菌门、厚壁菌门和拟杆菌门。总而言之，我们的研究为当归酮治疗 UC 的干预机制提供了新的视角。